Investigators retrospectively evaluated 8,243 consecutive minimally invasive gynecologic procedures performed between April 2019 and December 2024 at Keimyung University Dongsan Hospital. The analysis compared 6,109 patients treated with conventional laparoscopy and 2,134 patients treated with single-port robotic surgery using either the da Vinci Xi single-site or the da Vinci SP platform, as the authors reported. The dataset relied on pre-existing, de-identified clinical records and covered both benign and malignant gynecologic disease. The Institutional Review Board approved the study; the authors noted that consent was not applicable because the data were fully de-identified.
Data indicated a shorter total hospitalization after single-port robotic procedures compared with laparoscopy (reported means: 2.54 vs. 3.18 days; P < 0.001). Postoperative stay alone was also shorter in the robotic cohort (2.38 vs. 2.90 days; P < 0.001). The study team observed a lower transfusion frequency following robotic surgery: 0.6% versus 2.5% for laparoscopy (P < 0.001). These two outcome differences—reduced length of stay and lower transfusion rate—constituted the primary clinical advantages described in the report. The source did not provide detailed stratified outcomes by specific procedure type or pathology in the abstract, so granular subgroup performance cannot be inferred from the summary alone.
The authors reported no significant differences between groups in surgical site infection, overall postoperative complications, mortality, patient-controlled analgesia use, or 30-day readmission. In other words, the larger robotic cohort did not show a detectable increase in major perioperative adverse outcomes when compared with conventional laparoscopy. The study team therefore presented safety outcomes as broadly comparable across the two approaches in this real-world dataset.
Operative room time and anesthesia time each averaged approximately 8 minutes longer for the robotic procedures, according to the report. The authors did not report additional intraoperative time components or the learning-curve effects for the robotic platforms within the abstract text. Therefore, we cannot determine from the source whether the modest time increase reflected setup, docking, case mix, or surgeon experience.
Using differences in readmission, complication rates, and length of hospitalization, the investigators estimated hospital-based medical cost avoidance attributable to the robotic cohort. Across 2,134 robotic procedures, the reported aggregate avoidance was US$171,469, equating to roughly US$80.4 per robotic patient; reduced length of stay accounted for more than 84% of the total estimated savings. The source abstract did not provide a line-item cost model, unit costs, or the exact assumptions used to translate resource differences into dollars, so the reported figure should be interpreted as an institution-level estimate rather than a universally generalizable value.
This analysis used a large, single-center retrospective cohort and the Institutional Review Board approved the work (IRB No.: 2025-02-64). The authors declared no competing interests. The study design—retrospective review of de-identified records—limits causal inference and leaves unanswered questions about selection bias, detailed case mix, tumor stage distribution for malignant cases, and the impact of surgeon experience or institutional pathway changes over the study period. The abstract did not report subgroup-level outcomes by specific procedure type or provide the exact cost inputs for the economic estimate. The investigators concluded that these real-world findings support further prospective evaluation of the clinical and economic value of single-port robotic surgery in gynecology, and they recommended prospective study to confirm the observed reductions in postoperative resource use and to clarify the drivers of cost avoidance.
Limitations documented in the source therefore center on the retrospective design, single-center scope, and absence of granular cost-model disclosure or stratified outcome reporting in the abstract. Specific unanswered clinical questions that remain—based on the data presented—include how benefits vary by procedure type, how surgeon learning curves influence operative time differences, and whether the reported institutional cost avoidance replicates in other health systems with different unit costs or discharge practices.